MedPath

Study on presence of viral markers in neck lymph nodes in head and neck cancers(namely cancers of unknown primary , oropharynx and nasopharynx)

Not Applicable
Conditions
Health Condition 1: C119- Malignant neoplasm of nasopharynx,unspecifiedHealth Condition 2: C10- Malignant neoplasm of oropharynxHealth Condition 3: C799- Secondary malignant neoplasm of unspecified site
Registration Number
CTRI/2020/09/027522
Lead Sponsor
Dept of Otorhinolaryngology and Head and Neck Surgery
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1).All patients with cytologically or histologically proven metastatic squamous cell carcinoma , poorly differentiated and undifferentiated carcinoma to cervical lymph nodes in whom a primary lesion cannot be identified after a thorough routine examination of oral cavity, oropharynx, hypopharynx, nasopharynx and larynx in ENT OPD, including by nasal endoscopy, fibre optic/rigid telescopic examination of oropharynx, hypopharynx and larynx, and lacking an enhancing lesion/ definite mass suspicious of the primary on Contrast Enhanced Computed Tomography/Magnetic Resonance Imaging (MRI) from the skull base to the thoracic inlet (T4).

2).All cases of biopsy proven oropharyngeal carcinoma with cervical lymph node metastases

3).All cases of biopsy proven nasopharyngeal carcinoma with cervical lymph node metastases

4).Patient giving consent to participate in study

Exclusion Criteria

1).Patient who is not willing to participate in the study

2).Patient who is unfit for surgery under general anesthesia

3).Severe claustrophobia.

4).Pregnancy

5).H/o anaphylactoid reactions with intravenous contrast

for CT/ FDG for PET.

6).Presence of distant metastasis on 18FDG-PET-CT

7).Cases without adequate tissue in the FFPE block to perform IHC

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1).To know the prevalence of Human Papilloma Virus (HPV) in the cases of metastatic squamous cell carcinoma to cervical lymph nodes without a clinically or radiologically detected primary lesion in head and neck. <br/ ><br>2).To know the prevalence of Human Papilloma Virus (HPV) in cervical lymph node metastases from primary of oropharynx. <br/ ><br>3).To know the prevalence of Epstein Barr Virus (EBV-LMP1) in cervical lymph node metastases from primary of nasopharynx. <br/ ><br>Timepoint: 4 weeks to 8 weeks <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
To determine the HPV and EBV prevalence in India in cases of Carcinoma of unknown primary,CA nasopharynx and CA oropharynxTimepoint: 4 weeks to 8 weeks
© Copyright 2025. All Rights Reserved by MedPath